Kalvista Pharmaceuticals Inc 's ROA from the first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Kalvista Pharmaceuticals Inc 's ROA in the first quarter of 2026?
Kalvista Pharmaceuticals Inc recorded a cumulative net loss of $-185 million during 12 months ending in the first quarter of 2026, resulting in a negative return on assets (ROA) of -65.96%.

However, within the Healthcare sector 644 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 4083.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2026) I. Quarter	(Sep 30 2025) III. Quarter	(Jul 31 2025) I. Quarter	(Apr 30 2025) IV. Quarter	(Jan 31 2025) III. Quarter
Y / Y Total Assets Change	31.16 %	1.88 %	111.73 %	7.65 %	6.53 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-185	-210	-203	-183	-176
Return On Assets (TTM)	-65.96 %	-80.46 %	-78.03 %	-85.13 %	-83.09 %
KALV's Total Ranking	# 4083	#	# 4298	# 4426	# 4454
Total Assets (TTM) in million	329	240	339	216	251
Seq. Total Assets Change	37.14 %	-29.34 %	57.5 %	-14.06 %	6.53 %
Seq. Net Income Change	-	-	-	-	-

KALV's 5 Years Annual ROA >> Back to KALV Management Effectiveness >> Compare KALV ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 293
Sector	# 645
Overall	# 4048

Return On Assets Statistics
High	Average	Low
-16.55 %	-48.44 %	-94.19 %
(Jan 31 2019)		(Jul 31 2025)

News about Kalvista Pharmaceuticals Inc Return on Assets ROA

EKTERLY (Sebetralstat) A Potential Paradigm Shift in On-Demand Treatment for Hereditary Angioedema

CSIMarket.com KalVista Pharmaceuticals, Inc. has recently provided significant updates on its investigational drug, EKTERLY (sebetralstat), a novel oral on-demand treatment for hereditary angioedema (HAE). The recent presentations at the 20th German Allergy Congress and the European Academy of Allergy and Clinical Immunology (EAACI) Congress in 2025 highlighted the potential of sebetralstat to transform the management of HAE, particularly in patients requiring on-demand therapies during acute attacks.Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of severe swelling, which can be life-threatening and significantly impact quality of life. Current treatment options for HAE attacks include injectable therapies, which can be inconvenient and painful for patients. Sebetralstat, marketed as EKTERLY, is distinguished as the first and only oral medication designed specifically for the rapid treatment of these acute episodes.

Financial Statements
Kalvista Pharmaceuticals Inc 's Assets	$ 329 million	KALV's Balance sheet
Kalvista Pharmaceuticals Inc 's Income	$ -23 million	Quarterly KALV's Income Statement
KALV's Income by Division		See KALV's Income by Division

Annual Return On Assets	(Apr 30 2025) FY 2025	(Apr 30 2024) FY 2024	(Apr 30 2023) FY 2023	(Apr 30 2022) FY 2022	(Apr 30 2021) FY 2021
Y / Y Total Assets Change	6.53 %	28.49 %	-10.12 %	-25.07 %	193.98 %
Total Assets in million	251	235	183	204	272
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-183	-127	-93	-82	-46
Annual Return On Assets	-73.15 %	-53.8 %	-50.71 %	-40.4 %	-17 %

KALV's 5 Years Annual ROA >> Back to KALV Management Effectiveness >> Compare KALV ROA to its Competitors

More Return On Assets Ratios
KALV's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
KALV's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for KALV's Competitors
Subscribers only: Roa for Kalvista Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for KALV's Customers

You may also want to know
KALV's Roi	KALV's Inventory Turnover Ratio	KALV's Growth Rates	KALV's Dividend Comparisons
	KALV's Profitability Ratios	KALV's Asset Turnover Ratio	KALV's Dividend Growth
KALV's Roe	KALV's Valuation Ratios	KALV's Financial Strength Ratios	KALV's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:07:31+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.